

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

15th April 2026

Company: Chordia Therapeutics Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: IR Manager Ami Kira
MAIL : info@chordiatherapeutics.com

**Announcement of International Nonproprietary Name (INN)
for CTX-177**

Chordia Therapeutics Inc (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, “Chordia”) announced that the World Health Organization (WHO) has released the following International Nonproprietary Name (INN) for our MALT1 inhibitor CTX-177 as a recommended INN (rINN).

Development Code	International Nonproprietary Name (INN)
CTX-177	Ocipumaltib

An International Nonproprietary Name (INN) is the proper name for a medicinal substance that is common worldwide and is discussed and named by the World Health Organization (WHO). Since multiple pharmaceutical products may contain a single compound, giving a single standard name to a substance is expected to facilitate smooth communication regarding pharmaceutical drugs. Accordingly, we believe that the assignment of an International Nonproprietary Name (INN) to our development compound CTX-177 is a good step forward in our activities toward commercialization. We will use the generic name together with the Development Code for the development item for which the INN has been assigned.

About MALT1 inhibitor ocipumaltib (Development code : CTX-177)

Ocipumaltib is a selective inhibitor of mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), a protein known to play a pivotal role in intracellular signaling in lymphoid hematopoietic cells. Since activation of MALT1 has been reported to be essential in the oncogenic transformation of lymphoid cells, inhibition of MALT1’s activity by ocipumaltib is expected to demonstrate antitumor effects in lymphoid hematologic cancers.



About Chordia Therapeutics

Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177), CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website <https://www.chorditherapeutics.com/en/>.